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Abstract 
Background: Mucosal melanoma of the oral cavity is a rare entity and accounts for less than 
1–3% of all melanomas. Contrary to cutaneous melanoma, primary oral melanoma more 
commonly harbors mutations in c-KIT. Methods: A 64-year-old man presented with asymp-
tomatic, multiple, brown-to-black macules in the oral cavity. A biopsy was taken and histo-
pathology exhibited mucosal melanoma. In molecular analysis, a c-KIT mutation was proven 
and a CT scan revealed pulmonary metastases. Due to the multifocality of the lesions, the 
metastases, and the mutation status, a therapy with imatinib was initiated. Results: After  
1 year of therapy, progressive disease in the lung was noticed. Therefore, the therapy was 
switched to a PD-1 antagonist and a CTL-4 antibody. Conclusions: Our case suggests that 
imatinib may be considered as first-line treatment for both locally advanced and distant pri-
mary multifocal oral melanoma, for which surgery or radiotherapy of the primary tumor is 
impossible. © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
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A 64-year-old man was referred to our outpatient clinic because his dentist noticed mul-
tiple black-to-brown patches in the oral cavity. The patient had noticed the onset of pigmen-
tation about 1 month before. His past medical history was unremarkable, and he denied 
having symptoms such as burning and itching or using tobacco. A clinical examination re-
vealed multiple, partially confluent, brown-to-black macules in the whole oral cavity involv-
ing also the base of the tongue and the hard palate (Fig. 1). A differential diagnosis of mela-
nosis versus mucosal melanoma was made and a punch biopsy was taken. Histopathology 
exhibited mucosal melanoma (0.4 mm thickness; 2 mitoses/mm2). A molecular analysis of 
the specimens showed a c-KIT V560D mutation. BRAF and NRAS mutation assessments were 
negative. Laboratory test results including lactate dehydrogenase and S-100 levels were 
within normal ranges. Radiographic staging including whole-body CT scanning showed pul-
monary metastases. 
The case was presented to the interdisciplinary tumor board, where neither surgery nor 
radiotherapy was considered as a possible option to treat the primary tumor. Because of the 
locally advanced primary tumor and the metastases, and based on the mutation status, a 
targeted therapy with the tyrosine kinase inhibitor imatinib (400 mg once daily) was rec-
ommended and initiated. Three months later, a whole-body CT scan was performed, on 
which stable disease was noted. Moreover, the lesions in the oral cavity showed signs of 
regression, so that it was decided to continue the therapy. Regular follow-up and imaging 
evaluations every 3 months revealed stable disease of the pulmonary metastases and a par-
tial response of the primary melanoma (Fig. 2). However, at the last follow-up 14 months 
after treatment initiation, the CT scans revealed progressive disease in the lung. For this 
reason, the treatment with imatinib was stopped. The patient currently receives combina-
tion therapy with a PD-1 antagonist (nivolumab) and a CTL-4 antibody (ipilimumab). 
Discussion 
Our case highlights several problems related to the early diagnosis and adequate treat-
ment of multifocal primary oral melanoma. First, mucosal melanoma of the oral cavity is 
considered an exceedingly rare but highly aggressive form of melanoma, accounting for less 
than 1–3% of all melanomas. Accordingly, there is poor awareness about this melanoma 
subtype in the general population. Moreover, there are no defined risk factors such as a high 
nevus count or sun exposure habits that would help identifying persons at risk of developing 
oral mucosal melanoma. Although mechanical trauma, chronic infections of the oral cavity, 
and tobacco use were discussed as possible causal factors, their exact etiological role is still 
unclear [1–4]. 
Second, oral mucosal melanomas most commonly affect the hard palate or the maxillary 
alveolus. Occasionally, multiple foci are seen. The hidden localization and initial lack of 
symptoms may hamper early detection by the patient. In fact, the data suggest that melano-
ma of the oral cavity is often diagnosed at an advanced tumor stage (i.e., the 5-year relative 
survival is 25.5% for mucosal melanomas of the head and neck) [1–4]. 
Third, its clinical presentation is highly variable, with a broad spectrum of differential 
diagnoses such as mucosal melanosis, amalgam tattoo, mucosal nevi, lingua nigra, or even 
other infectious or inflammatory disorders [1–4]. 
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Forth, surgery is considered the mainstay in treating oral mucosal melanoma, followed 
by adjuvant radiotherapy. However, such treatment is often challenging, especially in the 
case of multifocal primary tumors. In our patient, surgery and radiotherapy were considered 
noncurative given the large extension of the primary tumor [1–4]. 
Fifth, in contrast to cutaneous melanoma, which shows BRAF mutation in 50% and 
NRAS mutation in about 20% of cases, primary oral melanoma more commonly harbors 
mutations in c-KIT. Although enormous progress has been made in the successful treatment 
of advanced cutaneous melanoma using targeted therapy and immune checkpoint inhibitors, 
the response rates and outcomes in the setting of metastatic mucosal melanoma are less 
promising. In particular, there is very limited knowledge about the use of targeted therapies 
in the treatment of primary mucosal melanoma [4, 5]. 
In the case of inoperable, locally advanced, or metastatic melanoma, systemic therapy is 
indicated. In this regard, an exact definition of the mutation status is unavoidable, since tar-
geted therapies nowadays are considered first- or second-line therapies. 
The recent retrospective analysis by Kim et al. [6] demonstrated BRAF inhibitors to be 
very effective in BRAF-mutated metastatic melanomas regardless of their subtype (cutane-
ous, acral, or mucosal). Altogether, 27 patients with BRAFV600E-mutated metastatic melano-
ma were included; 19 of them suffered from mucosal and acral melanoma. The objective 
response rate (ORR) was comparable in both groups (78.9% in the mucosal/acral melanoma 
group and 75.0% in the cutaneous melanoma group). The median progression-free survival 
(PFS) of all patients figured up to 9.2 months. PFS, however, was significantly better in pa-
tients who received a combination treatment with dabrafenib and trametinib than in those 
who were treated with vemurafenib alone. The ORR was nearly the same in both therapy 
regimes. 
However, BRAF mutations are rarely seen in mucosal melanomas, with a reported fre-
quency of 3.6–16.5%. Instead, nearly 25% of mucosal melanomas show a genetic aberration 
in KIT, a receptor tyrosine kinase [7–9]. Currently, the KIT inhibitor imatinib has been ap-
proved for the treatment of KIT-mutated melanoma. Imatinib is a tyrosine kinase inhibitor 
with potency against abl, c-kit, and platelet-derived growth factor receptor-β. The safety and 
efficacy of doses ranging from 400 to 800 mg daily have been well established. Besides its 
application in metastatic, KIT-mutated melanoma, it is used in patients with chronic myeloid 
leukemia and gastrointestinal stromal tumors [8]. 
It has to be emphasized that the response rates to the therapy significantly differ de-
pending on the KIT mutation status. In fact, Hodi et al. [7] reported data from a clinical trial 
using imatinib in metastatic mucosal, acral, or chronically sun-damaged melanomas. Overall, 
24 patients were included; 8 patients had a KIT mutation, 11 showed KIT amplification, and 
5 had both. The response rates to imatinib amounted to 54% in the mutated group and 0% 
in the amplified group. Furthermore, 4 patients in this study had an NRAS mutation before 
treatment; none of these had a response to or sustained stable disease with imatinib. These 
findings again confirm the model describing both the PI3K and the MAPK pathway as im-
portant downstream outputs in activated KIT in melanoma [7, 9]. 
In a retrospective analysis, Postow et al. [10] investigated the efficacy and safety of 
ipilimumab in patients with unresectable or metastatic mucosal melanoma. Twenty-two of 
the 33 included patients showed immune-related progressive disease 12 weeks after treat-
ment with ipilimumab. The median overall survival was 6.4 months, and although durable 
responses to ipilimumab were observed, the overall response rate was much lower than in 
cutaneous melanoma [10]. In a series of 71 patients in the Italian “early access program,” a 
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response rate of 12.5% and a 36% rate of stable disease with pretreated metastatic mucosal 
melanoma was observed [2, 11]. 
A recently published retrospective trial confirmed the response rates to anti-PD-1 
agents in mucosal melanoma to be comparable to the rates in patients with cutaneous mela-
noma [12]. The patients received either pembrolizumab or nivolumab as a monotherapy. 
The ORR was 23% and the PFS amounted to 3.9 months. A variety of trials using nivolumab, 
nivolumab plus ipilimumab, or ipilimumab alone have proved an advantage of nivolumab in 
the treatment of mucosal melanomas. The median PFS and response rate was 2.96 months 
and 23.2% for nivolumab, 5.85 months and 37.2% for nivolumab plus ipilimumab, and 2.69 
months and 8.3% for ipilimumab, respectively [2, 13]. 
In the most recent study by D’Angelo et al. [14], the efficacy and safety of nivolumab 
alone or in combination with ipilimumab in mucosal and cutaneous melanoma were com-
pared. It became apparent that, independently of the melanoma subtype, the median PFS 
and the ORR were much lower in the nivolumab-alone group than in the combination thera-
py group. Furthermore, grade 3 or 4 treatment-related adverse events were more frequent 
with the combination therapy, but comparable for both mucosal and cutaneous melanomas 
[14]. 
Conclusion 
In case of localized disease, surgical resection is still the optimal therapeutic approach 
and therefore standard of care. Due to the common multifocality and anatomic location of 
mucosal melanoma, surgery may be challenging or even impossible. In the case of localized 
but extensive disease, radiotherapy may be considered an alternative to surgery in order to 
achieve local tumor control. The role of sentinel lymph node biopsy is still controversially 
discussed, and there is a lack of clinical trials suggesting a benefit [15]. Hence, no recom-
mendations regarding the prognostic value of sentinel lymph node biopsy can be made. 
A variety of different therapeutic agents are available for the treatment of distant dis-
ease. If a BRAFV600E mutation is present, targeted therapy with a BRAF inhibitor in combina-
tion with a MEK inhibitor should be considered for first-line treatment, since response rates 
and PFS appear similar to those with BRAF-mutated cutaneous melanomas. In contrast to 
BRAF mutations, KIT mutations are more common in mucosal melanomas, and good re-
sponse rates to the tyrosine kinase inhibitor imatinib have been described. These data, how-
ever, are exclusively valid for KIT-mutated mucosal melanoma and not for KIT-amplified 
tumors (RR 54 vs. 0%). In wild-type advanced mucosal melanomas, the use of immuno-
oncological agents, especially nivolumab, provides valid data concerning ORR and PFS. How-
ever, no recommendations can be made regarding the duration of such therapies, nor are 
long-term data currently available. 
In conclusion, there is a need to increase our understanding of the tumor biology and 
molecular mechanisms of oral mucosal melanoma in order to enhance and personalize ther-
apeutic options. Currently, guidelines for treating this tumor are in development. Our case 
suggests that imatinib may be considered as a first-line treatment for both locally advanced 
and distant primary multifocal oral melanoma, for which surgery or radiotherapy of the 
primary tumor is impossible or associated with significant comorbidities or disfigurement. 
Treatment with imatinib achieved tumor control of both the primary tumor and the distant 
metastases for more than 1 year in our patient. Further studies are needed to prove a poten-
tial role of imatinib as first-line treatment for this challenging subtype of melanoma. 
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Fig. 1. Multiple, partially confluent, brown-to-black macules in the whole oral cavity also involving the base 




Fig. 2. Notable regression of the oral lesions 1 year after starting the treatment with imatinib at 400 mg 
once daily. 
 
